Increased mortality from complications of pulmonary hypertension in patients undergoing transcatheter aortic valve replacement

Raj Parikh1, Benson Varghese2, Huma N. Khatoon3, Julie A. Kovach3, Clifford J. Kavinsky3 and Rajive Tandon2

1Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA; 2Division of Pulmonary and Critical Care, Rush University Medical Center, Chicago, IL, USA; 3Division of Cardiology, Rush University Medical Center, Chicago, IL, USA

Abstract
Aortic stenosis (AS) leads to pulmonary hypertension (PH) and right ventricle (RV) failure. Our goal was to describe mortality related to postoperative complications in PH patients undergoing transcatheter aortic valve replacement (TAVR). Ninety-three TAVR patients were analyzed (controls, sPAP < 50 mmHg; cases, sPAP ≥ 50 mmHg). Significant findings in cases included increased mortality (365 days), post-TAVR atrioventricular block (AVB) and acute kidney injury (AKI), and increased mean length of stay (LOS). This novel study highlights complications of PH as independent risk factors for death and significant morbidity post TAVR. Optimization of preoperative volume status and RV afterload reduction, while addressing AVB and AKI, may play a vital role in reducing mortality and LOS.

Keywords
aortic stenosis, right ventricular failure, transcatheter aortic valve replacement (TAVR), pulmonary hypertension, atrioventricular block, mortality

Introduction
Aortic stenosis (AS) has a known consequence of pulmonary hypertension (PH) and right ventricle (RV) failure.1 Transcatheter aortic valve replacement (TAVR) has revolutionized treatment of AS by offering a less-invasive option compared to surgical aortic valve replacement (SAVR).2–4 Severity of AS is categorized as mild (Vmax 2–2.9 m/s or mean gradient < 20 mmHg), moderate (Vmax 3–3.9 m/s or mean gradient 20–39 mmHg), or severe (Vmax ≥ 4.0 m/s or mean gradient ≥ 40 mmHg).5 Patients who are candidates for AVR include both moderate and severe AS, as recent trials have shown the benefits of the Sapien S3 valve in the moderate AS population.6,7 The Placement of Aortic Transcatheter Valves (PARTNER) trial examined 358 patients with severe AS and compared balloon aortic valvuloplasty and TAVR.2,3 These results showed patients undergoing TAVR had lower mortality rates and improved New York Heart Association (NYHA) functional class. Another cohort of the PARTNER trial compared TAVR to SAVR and results demonstrated earlier symptom relief in the TAVR arm.8,9 Similarly, in the US CoreValve High Risk Study, 795 patients with severe AS were randomly assigned to TAVR and SAVR and results were significant for a reduced mortality rate in the TAVR arm.10

Establishing definitive therapy for AS is imperative as it can result in left ventricular hypertrophy with consequent dysfunctional lusitropy, leading to pulmonary vascular remodeling and development of Group 2 PH per the World Health Organization (WHO) classification.11–14

Corresponding author:
Raj Parikh, Department of Internal Medicine 1653 W. Congress Parkway, Chicago, IL 60612, USA.
Email: Raj.Parikh@Rush.edu

© The Author(s) 2017.
Reprints and permissions: sagedoc.co.uk/journalsPermissions.nav
journals.sagepub.com/home/pul
Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
development of PH in this population is primarily the result of elevated left-sided cardiac filling pressures and associated vascular reactive changes. Concurrent PH was seen in a study of 388 AS patients where right heart catheterization (RHC) showed evidence of mild–moderate PH, defined as systolic pulmonary artery pressure (sPAP) in the range of 31–50 mmHg, in 50% of patients and severe PH, defined as sPAP > 50 mmHg, in 15% of patients. Reports have indicated a prevalence of PH in AS patients in the range of 29–50%. Another investigation showed that nearly 70% of AS patients who are TAVR candidates also had concomitant PH.

Prior investigations were able to substantiate that AS patients undergoing AVR had decreased long-term survival though the reasons behind this worsened prognosis were not defined. Group 2 PH associated with postoperative TAVR complications needs further delineation given increasing utilization of TAVR. The aim of our study is to correlate postoperative complications, including mortality, in AS patients undergoing TAVR according to severity of PH.

Methods
Study design
We conducted a retrospective, post-hoc analysis of 93 consecutive AS patients who underwent TAVR from 2011–2015 at Rush University Medical Center, Chicago, IL, USA. The study was approved by the Institutional Review Board of Rush University Medical Center and the requirement for informed consent was waived. Patients undergoing SAVR were excluded. Primary outcomes evaluated the prospect that PH would predict mortality and length of stay (LOS) rates. Secondary outcomes included evaluation of postoperative complications, including mortality, acute kidney injury (AKI), and new post-procedural atroventricular block (AVB). AKI was defined by Kidney Disease: Improving Global Outcomes Clinical Practice Guidelines, where creatinine increased by ≥ 0.3 mg/dL within 48 h after surgery or a relative creatinine increase of ≥ 50% from the baseline within seven days after surgery. AVB, in this population, included the development of unstable bradycardia requiring permanent pacemaker placement as well as all degrees of heart block. Patients with a history of pacemaker prior to TAVR were excluded from the AVB outcomes.

Data extraction
Clinical and laboratory data were collected for all patients at various time intervals including pre-procedure, peri-procedure, post-procedure, during the index hospitalization, and up to one year post procedure when available. Collected data included past medical history, laboratory tests, trans-thoracic echocardiograms (TTE) studies, RHC results, and clinical outcomes including postoperative complications. RHCs were completed at time of TAVR procedure by interventional cardiologists.

Statistical analysis
Baseline characteristics, results of RHC, peri-procedural characteristics, postoperative complications, and LOS between none/mild PH and moderate/severe PH were compared by one-way ANOVA and Fisher’s exact test. A P value of < 0.05 was considered statistically significant. Mortality rates up to 365 days were computed when data were available. Follow-up was noted up to 365 days since TAVR procedure. Additionally, for patients with available data, a linear regression model with LOS (in days) as dependent and pre-TAVR BNP as independent was performed. All data analysis was performed using SPSS statistical software.

Several multiple logistic regression models were performed on post-procedure AKI, post-procedure AVB, and mortality at 120 and 365 days as dependent variables and all the usable clinical variables collected in the study entered as candidate independent variables. For each dependent variable analyzed, candidate predictors were entered stepwise into the model whenever the estimated P value for their associated test F statistic was < 0.05. They were eliminated from the model when the F statistic was > 0.1. Candidate variables were entered in the order of smallest P value first. Odds ratios (OR) were generated and expressed with 95% confidence intervals (CI). A multiple linear regression was also performed on LOS in days against previously identified candidate predictors outliers with two ICU LOS removed (< 3% of the 93 cases) to minimize the impact of outliers on the regression.

Results
A total of 93 patients were included in the study. Patients were divided into two groups based on severity of PH, which was determined by sPAP recorded from RHC during the TAVR. The sPAP was averaged over three respiratory cycles and patient were anesthetized at the time of measurement. Controls were defined as none/mild PH with sPAP < 50 mmHg (n = 50) and cases were defined as moderate/severe PH with sPAP ≥ 50 mmHg (n = 43).

Baseline characteristics were compared between the two groups (Table 1). The total population had comparable morbidity rates, including hypertension, diabetes mellitus (DM), chronic obstructive lung disease, renal failure requiring hemodialysis, and prior cardiac valve surgery. The incidence of coronary artery disease (CAD) was significantly greater in the controls (66.0% controls versus 44.2% cases; P = 0.035) while the incidence of atrial fibrillation (AF) was greater in the cases (30.0% controls versus 46.5% cases; P = 0.770), though not statistically significant. Both cohorts, additionally, had a similar percentage of severe AS patients (20.0% controls versus 22.4% cases; P = 0.982).
LOS and mortality were evaluated as primary outcomes (Table 2). The mean difference in total LOS was 3.6 days ($P = 0.008$) and the mean difference in LOS after procedure was 2.6 days ($P = 0.016$) between the cases and controls. Mortality was statistically significant between the controls and cases at 120 days (6.5% controls versus 20.9% cases; $P = 0.046$; Fig. 1) and 365 days (14.7% versus 41.9%; $P = 0.014$; Fig. 2).

Secondary outcomes included procedural complications (Table 3). The incidence of AKI in the postoperative period was significantly lower in controls (6.4% controls versus 34.2% cases; $P = 0.001$). Increased pre-TAVR BNP, in both cases and controls, correlated significantly with the development of AKI (BNP < 500 pg/mL: 4.6% versus BNP $\geq$ 500 pg/mL: 30.4%; $P = 0.011$; Table 4). There was also an increased incidence of new AVB (9.8% controls versus 31.6% cases; $P = 0.016$) and temporary pacemaker implantation (4.9% controls versus 26.3% cases; $P = 0.009$) in the cases (Table 3).

Among multivariable analyses performed for prediction of AKI after TAVR, moderate/severe PH was found to be the strongest predictor with an OR of 9.5 (95% CI, 2.0–44.8). Additional variables that were found to be predictors of AKI after TAVR included chronic kidney disease (OR = 6.6; 95% CI, 1.4–30.6) and female sex (OR = 6.2; 95% CI, 1.3–30.6).

Among multivariable analyses preformed for prediction of AVB after TAVR, moderate/severe PH was found to be the strongest predictor with an OR of 20.6 (95% CI, 3.4–126.1). Additional variables that were found to be predictors of post-procedure AVB included use of Sapien THV (OR = 6.8; 95% CI, 1.063–43.6) and significant CAD (OR = 7.1; 95% CI, 1.4–37.0), whereas chronic AF was found to be a negative predictor (OR = 0.12; 95% CI, 0.02–0.8).

Multivariable analyses were performed for mortality at 120 and 365 days. AKI post-procedure was the only significant predictor (OR = 33.3; 95% CI, 6.0–183.8) for mortality at 120 days (Fig. 3). Post-procedure AVB was the strongest predictor for mortality at 365 days (OR = 10.4; 95% CI, 1.4–79.6). Post-procedure AKI was also a significant

### Table 1. Baseline co-morbidities of controls and cases (n (%)).

| Co-morbidities                              | Controls | Cases | OR  | P    |
|---------------------------------------------|----------|-------|-----|------|
| Systemic hypertension                       | 43 (86.0) | 39 (90.7) | 1.59 | 0.356|
| Diabetes mellitus                          | 18 (36.0) | 17 (39.5) | 1.16 | 0.831|
| Chronic obstructive pulmonary disease       | 16 (32.0) | 13 (30.2) | 0.92 | 0.517|
| Renal failure requiring hemodialysis        | 3 (6.0)   | 4 (9.3)   | 1.61 | 0.415|
| Prior cardiac valve surgery                 | 3 (6.0)   | 4 (9.3)   | 1.61 | 0.415|
| Atrial fibrillation                         | 15 (30.0) | 20 (46.5) | 2.03 | 0.770|
| CAD ($>$ 50% stenosis, prior PCI, CABG)     | 33 (66.0) | 19 (44.2) | 0.41 | 0.028|
| Mean age (years)                            | 83.6      | 79.4   | –   | 0.392|

### Table 2. Mortality (%) between controls and cases.

| Mortality intervals | Controls | Cases | OR  | P  |
|---------------------|----------|-------|-----|----|
| Mortality at 60 days| 6.0      | 14.0  | 2.54| 0.173|
| Mortality at 120 days| 6.5    | 20.9  | 3.79| 0.046|
| Mortality at 365 days| 14.7  | 41.9  | 4.19| 0.014|

Fig. 1. Kaplan–Meier curve for 120-day mortality. Moderate/Severe PH group with increased mortality at 120 days ($P = 0.046$).
predictor of mortality at 365 days (OR, 6.5; 95% CI, 1.4–30.7; Fig. 4).

Multiple linear regression analysis showed LOS was associated with pre-TAVR BNP, moderate/severe PH, CAD, and post-procedure respiratory failure. The multiple R-value for the regression was 0.56 while $R^2$ was 0.31, indicating that the multiple linear regression accounts for approximately 31% of the variance in LOS.

**Discussion**

**BNP and pulmonary hypertension**

The correlation between BNP and AF in PH was investigated in our study. A higher incidence of preoperative AF was identified in patients with AS with moderate/severe PH undergoing TAVR versus none/mild PH, as shown in previous studies. The increased prevalence of AF in this population is presumably a result of post-capillary PH causing left atrial stretch. Right ventricular dilatation, along with atrial stretch, may play a role in triggering this arrhythmia (Fig. 5). A trend towards increased pre-TAVR AF in moderate/severe PH can be attributed to increased atrial stretch due to passive congestion from AS, which is reflected by higher mean BNP levels in the moderate/severe PH group (pre-TAVR BNP 726.9 pg/mL controls versus pre-TAVR BNP 1869.5 pg/mL cases; $P = 0.135$).

**Mortality, cardiac remodeling, and LOS**

Our study shows significant higher mortality rates correlating with PH severity at 120 (20.9%) and 365 days (41.9%) post TAVR, consistent with larger cohorts showing 30-day (14.5%), 365-day (30.8%), and two-year (48.4%) mortality. The FRANCE-2 registry also showed an increase in 365-day mortality (20.8%) in moderate and severe PH

---

**Table 3.** Post-procedural complications between controls and cases (n (%)).

| Complication                        | Controls | Cases | OR  | P   |
|-------------------------------------|----------|-------|-----|-----|
| Myocardial infarction               | 0 (0.0)  | 2 (4.8)| 1.05| 0.209|
| Need for surgical AVR               | 1 (2.0)  | 1 (2.4)| 1.20| 0.707|
| Stroke                              | 2 (4.0)  | 2 (4.8)| 1.20| 0.623|
| Acute kidney injury                 | 3 (6.4)  | 13 (34.2)| 7.63| 0.001|
| Respiratory failure                 | 6 (12.0) | 7 (16.7)| 1.47| 0.366|
| Heart failure                       | 3 (6.0)  | 2 (4.8)| 0.78| 0.583|
| New atrial fibrillation             | 3 (6.0)  | 3 (7.2)| 1.21| 0.575|
| Atrioventricular block              | 4 (9.8)  | 12 (31.6)| 4.27| 0.016|
| Temporary pacemaker                 | 2 (4.9)  | 10 (26.3)| 6.96| 0.009|
| Any infection                       | 4 (8.0)  | 4 (9.5)| 1.21| 0.541|

**Table 4.** Pre-TAVR BNP levels associated with post-TAVR complications (%).

| Complication                        | Pre-TAVR BNP < 500 pg/mL | Pre-TAVR BNP ≥ 500 pg/mL | OR  | P   |
|-------------------------------------|---------------------------|---------------------------|-----|-----|
| Stroke                              | 0.0                       | 8.7                       | 2.00| 0.256|
| Acute kidney injury                 | 4.6                       | 30.4                      | 1.30| 0.013|
| Respiratory failure                 | 18.2                      | 21.7                      | 1.75| 0.374|
| Heart failure                       | 0.0                       | 8.7                       | 1.13| 0.125|
| New atrial fibrillation             | 4.6                       | 4.4                       | 0.96| 0.745|
patients. Our study, however, uses RHC to define severity of PH rather than TTE, which may be more accurate as a measure of pulmonary vascular resistance (PVR) in this population.

Cardiac remodeling can contribute to the increased mortality in the moderate/severe PH group as well. In severe AS, geometric remodeling of the left ventricle is a known complication. However, with concomitant PH, increased PVR with subsequent remodeling of the RV may further contribute to excess mortality. In addition to cardiac remodeling, post-TAVR complications of PH (AKI and AVB) contribute to worsened mortality at 120 and 365 days.

Along with increasing complications in the post-TAVR period and the subsequent increased rates of mortality, cases also had a longer LOS compared with controls. Pre-TAVR elevated BNP (in all TAVR patients) is an independent predictor of morbidity correlating to increased LOS as well. This suggests maintaining preoperative euvolemia and
addressing elevated RV diastolic parameters may help improve outcomes and decrease LOS in these patients.

**Atrioventricular block**

The development of new AVB (post-TAVR) is a novel finding in AS patients with moderate/severe PH, not reported in previous studies. AVB is a known complication in TAVR patients, especially those with specific co-morbidities including prior cardiac conduction abnormalities, heart failure, hypertension, and DM. AVB is thought to be due to the proximity of the coronary orifice and conduction system to the aortic valve annulus, which may be impinged upon by the prosthesis. While long-standing PH can lead to pre-existing dysfunction of the right-sided conduction system, a significant history of right bundle branch block was not noted in our cohort of patients. If this were to exist, further disruption of the left-sided conduction system by the underlying aortic valve disease process and the new prosthetic valve, could result in complete heart block and the need for permanent pacing; however, this would only be present in severe cases of PH and not in mild or moderate cases. The presence of AVB in our moderate/severe PH cases was also associated with an increased incidence of pacemaker placement. Our study also suggests that prosthetic valve type contributes to the incidence of new AVB post procedure, as the Sapien THV was shown to be an independent predictor of heart block in the cohort.

**Acute kidney injury**

Post-TAVR AKI was another significant complication seen in the moderate/severe PH group. AKI in TAVR patients has been shown to have a strong correlation with postoperative mortality. Prior investigations highlight preoperative renal impairment, transapical versus transfemoral TAVR approach, and need for circulatory support as the major contributing risk factors for post-procedural AKI. In our study, the presence of moderate/severe PH at the time of TAVR was significantly associated with the development of post-TAVR AKI. Pre-procedural volume status with elevated BNP correlated directly with post-TAVR AKI, suggesting that maintaining preoperative euvolemia and potentially addressing increased PVR may modify AKI outcomes.

Studies have shown that PH patients with subsequent RV failure have a stimulated renin-angiotensin-aldosterone system (RAAS) axis. Additionally, electrolyte abnormalities, including hyponatremia, are associated with poorer outcomes in PH patients. The presumed physiology leading to AKI is a result of arterial underfilling due to poor cardiac output, which triggers RAAS and thereby increases sodium and water retention. Additionally, RV failure serves to increase renal venous pressure and hence, decrease the kidney’s glomerular filtration rate, which increases sodium and water retention. These mechanisms define the cardiorenal syndrome that develops in patients with PH and RV failure. This subset of patients has a tenuous fluid status from low cardiac output that ultimately leads to kidney perfusion injury. Identifying patients at risk for AKI is essential as our study showed a significant correlation between AKI and post-TAVR mortality at 120 and 365 days.

**Limitations**

This study was a post-hoc analysis and therefore is subject to the generalized limitations of retrospective analyses, including the potential role of unknown confounders. In regards to our cohort of patients, we did not distinguish...
between PH secondary to AS versus other etiologies of PH although other causes for PH were evaluated and excluded. Our sample size was limited due to recent initiation of the TAVR program at our institution; this limitation in patient cohort lends to the possibility of Type 2 errors in our statistical analysis.

We chose to define severity of PH in two separate subsets based on sPAP from RHC at time of TAVR. Because we were not able to calculate PVR or transpulmonary gradient from the RHC at time of TAVR (due to lack of recording cardiac output and pulmonary artery occlusion pressure), we chose to delineate severity of PH based solely on sPAP recorded at RHC. The absence of these hemodynamic measurements, including cardiac output, served to obscure the observations from our study. This severity scoring has been validated in two prior studies by Melby et al. and Yong et al.\textsuperscript{15,19,33}

AKI was presumed to be a result of poor cardiac output from group 2 PH; however, we are only able to establish an association and not causality of a cardiorenal process due to lack of cardiac output measurements.

**Conclusions**

Our study shows that complications from PH are independent predictors of poor outcomes post TAVR. This retrospective analysis highlights the importance of preoperative optimization in AS patients with concomitant PH. Such optimization could potentially include addressing fluid balance and prophylactic pacemaker implantation in high-risk patients. Additionally, a multivariable analysis that can determine whether sPAP > 50 mmHg is a strong independent predictor of post-procedural AKI and AVB would also serve as a complement to our investigation.

Further prospective studies with pulmonary vasodilators, pre-procedural volume optimization, and prophylactic pacemakers are warranted to decrease postoperative TAVR complications and improve mortality in this PH subset. Increased short-term and long-term mortality, together with AKI and AVB, highlights how pre-existing PH may complicate outcomes in this frail population.

**Conflict of interest**

The authors declare that there is no conflict of interest.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**References**

1. Silver K, Aurigemma G, Krendel S, et al. Pulmonary artery hypertension in severe aortic stenosis: incidence and mechanism. *Am Heart J* 1993; 125: 146–150.

2. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010; 363: 1597–1607.

3. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. *N Engl J Med* 2012; 366: 1696–1704.

4. Criber A, Eltchaninoff H, Tron C, et al. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. *J Am Coll Cardiol* 2004; 43: 698–703.

5. Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. *Eur Heart J* 2007; 28: 230–268.

6. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014; 63: e57–e185.

7. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. *N Engl J Med* 2016; 374: 1609–1620.

8. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med* 2011; 364: 2187–2198.

9. Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. *N Engl J Med* 2012; 366: 1686–1695.

10. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med* 2014; 370: 1790–1798.

11. Simonneau G, Robbins I, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2009; 54: S43–S54.

12. Casaeliang-Verzosa G, Nkomo VT, Sarano ME, et al. E/Ea is the major determinant of pulmonary artery pressure in moderate to severe aortic stenosis. *J Am Soc Echocardiogr* 2008; 21: 824–827.

13. Kapoor N, Varadarajan P and Pai RG. Echocardiographic predictors of pulmonary hypertension in patients with severe aortic stenosis. *Eur J Echocardiogr* 2008; 9: 31–33.

14. Mutlak D, Aronson D, Carasso S, et al. Frequency, determinants and outcome of pulmonary hypertension in patients with aortic valve stenosis. *Am J Med Sci* 2012; 343: 397–401.

15. Faggiano P, Antonini-Canterin F, Ribichini F, et al. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. *Am J Cardiol* 2000; 85: 204–208.

16. Johnson LW, Hapanowicz MB, Buonanno C, et al. Pulmonary hypertension in isolated aortic stenosis. Hemodynamic correlations and follow-up. *J Thorac Cardiovasc Surg* 1988; 95: 603–607.

17. Pai RG, Varadarajan P, Kapoor N, et al. Aortic valve replacement improves survival in severe aortic stenosis associated with severe pulmonary hypertension. *Ann Thorac Surg* 2007; 84: 80–85.

18. Ben-Dor I, Goldstein SA, Pichard AD, et al. Clinical profile, prognostic implication, and response to treatment of pulmonary hypertension in patients with severe aortic stenosis. *Am J Cardiol* 2011; 107: 1046–1051.

19. Melby SJ, Moon MR, Lindman BR, et al. Impact of pulmonary hypertension on outcomes after aortic valve replacement for aortic valve stenosis. *J Thorac Cardiovasc Surg* 2011; 141: 1424–1430.
20. Lindman BR, Zajarias A, Maniar HS, et al. Risk stratification in patients with pulmonary hypertension undergoing transcatheter aortic valve replacement. *Heart* 2015; 101: 1656–1664.

21. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007; 11: R31.

22. Barbash IM, Escarcega RO, Minha S, et al. Prevalence and impact of pulmonary hypertension on patients with aortic stenosis who underwent transcatheter aortic valve replacement. *Am J Cardiol* 2015; 115: 1435–1442.

23. Olsson KM, Nickel NP, Tongers J, et al. Atrial flutter and fibrillation in patients with pulmonary hypertension. *Int J Cardiol* 2013; 167: 2300–2305.

24. Schnabel RB, Larson MG, Yamamoto JF, et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. *Circulation* 2010; 121: 200–207.

25. Lucon A, Oger E, Bedossa M, et al. Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: study from the FRANCE 2 registry. *Circ Cardiovasc Interv* 2014; 7: 240–247.

26. Rossi A, Enriquez-Sarano M, Burnett JC Jr, et al. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. *J Am Coll Cardiol* 2000; 35: 1256–1262.

27. Neragi-Miandoab S and Michler RE. A review of most relevant complications of transcatheter aortic valve implantation. *ISRN Cardiol* 2013; 2013: 956252.

28. Steinberg BA, Harrison JK, Frazier-Mills C, et al. Cardiac conduction system disease after transcatheter aortic valve replacement. *Am Heart J* 2012; 164: 664–671.

29. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *Eur Heart J* 2012; 33: 2403–2418.

30. Webb JG, Chandavimol M, Thompson CR, et al. Percutaneous aortic valve implantation retrograde from the femoral artery. *Circulation* 2006; 113: 842–850.

31. Schrier RW and Bansal S. Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure? *Clin J Am Soc Nephrol* 2008; 3: 1232–1237.

32. Rabinovitz A, Raiszadeh F and Zolty R. Association of hyponatremia and outcomes in pulmonary hypertension. *J Card Fail* 2013; 19: 550–556.

33. Yong G, Khairy P, De Guise P, et al. Pulmonary arterial hypertension in patients with transcatheter closure of secundum atrial septal defects. *Circ Cardiovasc Interv* 2009; 2: 455–462.